PET-FDG in Myocarditis

Myocarditis Clinical Trial

— PETMYO  

Official title:

Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography Imaging in Myocarditis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03777839
• Other study ID #: 2019-2395
• Status: Completed
• Start date: November 20, 2018
• Est. completion date: August 1, 2023

Study information

• Verified date: October 2023
• Source: Montreal Heart Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study evaluates the diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) with rest perfusion imaging for the diagnosis of myocarditis. Patients with clinical suspicion of myocarditis will be recruited and undergo a rest myocardial perfusion scan and a FDG PET/CT scan following a myocardial suppression protocol.

Description:

Myocarditis is characterized by myocardial inflammation, which can lead to fibrosis and heart failure.

FDG PET/CT, with appropriate suppression protocol including high-fat-low-carbohydrate diet, fasting, and IV heparin, can be use to detect myocardial inflammation. It is frequently used for the diagnosis of inflammation in cardiac sarcoidosis. After the initial inflammatory phase, inflammation resolves and fibrosis can seen. Resting perfusion imaging will allow identification of fibrosis. The combination of FDG PET/CT and rest perfusion imaging could allow detection of the various phases of myocarditis; inflammation and fibrosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: August 1, 2023
• Est. primary completion date: August 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. 18 years of age or older

2. Clinical suspicion of myocarditis due to findings such as:

1. Symptoms and signs of myocarditis such as dyspnea, orthopnea, palpitation, and chest pain, without other identifiable cause

2. New onset of cardiovascular symptoms with recent history of viral disease or previous myocarditis

3. Unexplained new onset of left ventricular dysfunction

4. Unexplained elevated troponin

5. Magnetic resonance imaging findings suggestive of myocarditis, such as late gadolinium enhancement and edema

6. Biopsy findings compatible with myocarditis

3. Women of childbearing potential must have a negative urine or blood pregnancy test

4. Capable of giving informed consent and the consent must be obtained prior to any study related procedures

5. Subject's with body mass index inferior or equal to 45 kg/m2

Exclusion Criteria:

1. Female subject who is pregnant or breastfeeding and unwilling to stop for 24h

2. Claustrophobia or inability to lie still in a supine position for imaging purposes

3. Unwillingness or inability to provide informed consent

Related Conditions & MeSH terms

• Myocarditis
• Viral Myocarditis

Intervention

Diagnostic Test:
• FDG PET/CT
FDG PET CT imaging with rest perfusion imaging

Locations

Country	Name	City	State
Canada	Matthieu Pelletier-Galarneau	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Montreal Heart Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity of FDG PET/CT imaging with rest perfusion imaging to detect myocarditis	Sensitivity of FDG-PET/CT with rest perfusion imaging	1 year
Secondary	Specificity and accuracy of FDG-PET/CT with rest perfusion imaging to detect myocarditis	Specificity and accuracy of FDG-PET/CT with rest perfusion imaging	1 year
Secondary	Left ventricular ejection fraction	The association between subjects' outcome and quantitative assessment of left ventricular inflammation and scar will be evaluated	1 year